J. Brantley Thrasher, MD, professor of urology, University of Kansas, Kansas City
Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy. N Engl J Med 2017; 377:338-51.
This trial tested the use of abiraterone with ADT versus ADT alone in men with locally advanced or metastatic prostate cancer and showed a significant survival benefit to those receiving abiraterone as first-line therapy in lieu of late in the disease.
Radiation with or without Antiandrogen Therapy in Recurrent Prostate Cancer. N Engl J Med 2017; 376:417-28.
This trial showed that the addition of 24 months of antiandrogen therapy, in the form of bicalutamide (Casodex) daily, to salvage radiation therapy in men with biochemical recurrence following radical prostatectomy improved long-term survival and lowered the incidence of metastatic disease and death from prostate cancer.
More from Urology Times:
To get weekly news from the leading news source for urologists, subscribe to the Urology Times eNews.